Drug Search Results
More Filters [+]

Linzagolix

Alternative Names: linzagolix, klh-2109, klh2109, klh 2109, obe-2109, obe2109, obe 2109
Latest Update: 2024-04-22
Latest Update Note: PubMed Publication

Product Description

Linzagolix is a novel, orally administered GnRH receptor antagonist that potentially provides effective management of endometriosis-associated pain while mitigating bone mineral density loss and other adverse effects typically associated with currently approved treatments. Unlike marketed GnRH agonists, Linzagolix has the potential to be administered orally once a day, with symptoms relieved within days, while potentially mitigating the initial worsening of symptoms often associated with GnRH agonist treatments. (Sourced from: https://www.obseva.com/linzagolix/)

Mechanisms of Action: GnRH Antagonist

Novel Mechanism: No

Modality: Small Molecule

Route of Administration: Oral

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: Belgium | Croatia | Czech | European Medicines Agency | Finland | Germany | Hungary | Iceland | Ireland | Italy | Latvia | Lithuania | Poland | Portugal | Slovakia | Sweden

Approved Indications: None

Known Adverse Events: None

Company: ObsEva
Company Location: PLAN-LES-OUATES V8 1228
Company CEO:
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Linzagolix

Countries in Clinic: Austria, Bulgaria, Czech Republic, France, Hungary, Japan, Poland, Romania, Spain, Ukraine, United States

Active Clinical Trial Count: 9

Highest Development Phases

Phase 3: Endometriosis|Injuries/wounds Unspecified|Leiomyoma|Menorrhagia|Myofibroma

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

jRCT2031220180

P3

Recruiting

Menorrhagia

2025-05-31

KLH2301

P3

Active, not recruiting

Leiomyoma|Menorrhagia|Myofibroma

2025-05-01

35%

jRCT2031220181

P3

Recruiting

Menorrhagia

2024-09-30

KLH2302

P3

Active, not recruiting

Myofibroma|Menorrhagia|Leiomyoma

2024-09-01

35%

Recent News Events